1 in 6
Infections resistant to antibiotics
Among laboratory-confirmed common bacterial infections worldwide in 2023.
WHO · 2025 report ↗RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING
Faster answers.Less waiting.
We are developing rapid susceptibility testing to shorten the journey from clinical sample to result — bringing clarity to antibiotic decisions sooner.
Technology in validation · Built on over a decade of research
FROM CLINICAL SAMPLES. TOWARDS EARLIER ANSWERS.↓
01 /THE CHALLENGE
Resistance is rising. Answers need to come sooner.
Drug-resistant infections place a growing burden on patients, healthcare systems and economies. Knowing how bacteria respond to antibiotics is an essential part of the response.
4.7M+
Deaths associated with bacterial AMR
Estimated worldwide in 2021. Associated deaths are distinct from deaths directly attributable to resistance.
WHO · 2026 fact sheet ↗US$412B
Projected annual treatment costs
For resistant bacterial infections through 2035, under current levels of action. A projection, not a measured current cost.
WHO · 2026 fact sheet ↗Our focus: shortening the wait for antimicrobial susceptibility results.
↓02 /OUR APPROACH
Start with the sample. Read the bacterial response.
We combine rapid bacterial isolation and enrichment with monitoring of bacterial metabolism to determine antimicrobial susceptibility.
01
Isolate & enrich
Recover and concentrate bacteria from clinical samples, preparing them for susceptibility testing.
02
Measure metabolism
Monitor bacterial metabolic activity in response to antibiotics to reveal susceptibility.
03
Deliver earlier insights
Generate susceptibility results with a focus on reducing the full time from sample collection to result.
A technology under validation, with urine and blood samples as our initial focus.
03 /OUR PROGRESS
Research behind us. Possibility ahead.
Preliminary clinical validation shows good categorical agreement with the clinical reference method, alongside substantially shorter sample-to-result turnaround times.
10+
years of foundational research
300+
clinical samples evaluated
Validation in progress. Not yet a commercial product.
From sample collection to result
MEAN TURNAROUND TIMEUrine samples
507h
Blood samples
10013h
The clock starts at sample collection — not at blood culture positivity.
About these validation results
Source: preliminary clinical validation data supplied by the Metallix team, covering more than 300 clinical samples. Times shown are sample-type mean turnaround times from collection to susceptibility result; comparator times were measured using the hospital’s existing workflow. These are preliminary observations under the evaluated conditions, not guaranteed performance for every sample. Further validation and product development are ongoing.
04 /LET’S MOVE FORWARD
Bring the next chapter closer. Together.
We welcome industry partners and investors who share our ambition to advance rapid susceptibility testing, alongside clinical collaborators for the next stage of validation.
info@metallixmed.com01Industry partnerships02Investment conversations03Clinical collaboration
Start a conversation. Shape what comes next.